ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss

ProQR Therapeutics has encouraging data from an early-stage study evaluating its treatment for vision loss in the rare, inherited disorder Usher syndrome. The biotech now plans to advance its RNA therapy to two pivotal studies later this year.